A Cross Sectional Study Evaluating the Mean Levels of Alpha Fetoprotein in Patients of Hepatocellular Carcinoma and Its Correlates in Pakistan
Completed
- Conditions
- Carcinoma, Hepatocellular
- Registration Number
- NCT06629857
- Lead Sponsor
- Darul Sehat Hospital
- Brief Summary
This study aims to explore the levels of alpha-fetoprotein (AFP), a protein often elevated in liver cancer, in patients with hepatocellular carcinoma (HCC). The goal is to determine whether AFP levels vary based on the size of the liver tumor or other health conditions like hepatitis B, hepatitis C, and obesity. By analyzing data from 94 patients, the study seeks to identify factors that influence AFP levels, which may help in understanding liver cancer progression and improving diagnosis and treatment approaches.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 94
Inclusion Criteria
- Aged between 27 to 80 years.
- Diagnosed with hepatocellular carcinoma (HCC) within the last three months.
- Diagnosis confirmed by relevant investigations (e.g., imaging, liver biopsy).
- Able to provide informed consent.
Exclusion Criteria
- Elevated alpha-fetoprotein levels due to tumors other than HCC.
- Presence of secondary liver metastases from other primary sites.
- Any significant comorbid conditions that could interfere with study assessments.
- Pregnancy or breastfeeding.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Mean Alpha-Fetoprotein (AFP) Levels in HCC Patients Baseline measurement at time of diagnosis.
- Secondary Outcome Measures
Name Time Method Correlation Between AFP Levels and Tumor Size At baseline (upon diagnosis).
Trial Locations
- Locations (1)
Darul Sehat Hospital
🇵🇰Karachi, Sindh, Pakistan